Covaxin gets WHO approval

  • In a major development WHO's Technical Advisory Group which was scheduled to meet today to decide the fate of Covaxin, has finally granted Emergency Use Listing (EUL) status to the vaccine

  • This would mean that all those who have taken Covaxin need to self-quarantine in other countries and hence ensure ease of traveling

  • Further, this would allow the Made-in-India vaccine to be available for Global use

  • the vaccine was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended use of this vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above

  • WHO said that covaxin was found to be 78% effective against COVID-19 after the second dose. Further, it was extremely suitable for low and middle-income countries due to ease of storage

D9D318A1-A861-4CFD-94ED-B72F5EDD67F3_edi

Subscribe to us

Thanks for submitting!

intern%20with%20us_edited.jpg
  • Instagram
  • Twitter
  • LinkedIn
  • Facebook

INDEPENDENT.

OBJECTIVE.

UNBIASED. 

the breif bulletin logo